Beta Bionics, Inc.
For the period ended Sep 30, 2026. Filed Oct 27, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plan
During the three months ended September 30, 2026, the following officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated the contracts, instructions or written plans for the purchase or sale of securities of our company set forth in the table below.
| Name and Position | Action | Date | Rule 10b5-1* | Total Shares to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Stephen Feider, Chief Financial Officer | Adoption | July 31, 2026 | X | 80,000 | October 29, 2027 |
| Sean Saint, President and Chief Executive Officer | Adoption | August 20, 2026 | X | 320,000 | December 31, 2027 |
| Maria Palasis, Director | Adoption | August 25, 2026 | X | 13,994 | June 30, 2027 |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.